Research Topics
Genomes and Genes
| A Mark RichardsSummaryCountry: New Zealand Publications
| Collaborators
|
Detail Information
Publications
Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
Eur Heart J 26:2055-62. 2005..To investigate the subacute effects of a sustained intravenous infusion of urocortin-I (Ucn-I) in experimental heart failure (HF)...
Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohortBarry R Palmer
Department of Medicine, Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
Am Heart J 156:752-8. 2008..We tested the hypothesis that the rare allele of an ACE2 gene polymorphism was associated with risk factors for and adverse outcome after acute coronary syndrome (ACS) events...
Urotensin II in the cardiovascular systemA Mark Richards
Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Riccarton Avenue, P O Box 4345, Christchurch, New Zealand
Peptides 25:1795-802. 2004..The place of urotensin II in the chronic trophic responses to cardiac and vascular injury and its possible roles as a neurotransmitter and/or regulator of renal and endocrine function remain largely unexplored...
NT-proBNP in heart failure: therapy decisions and monitoringMark Richards
Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
Eur J Heart Fail 6:351-4. 2004..Finally, adjustment of therapy for heart failure according to serial measurements of NT-proBNP promises to improve outcomes in comparison with adjusting therapy according to unassisted clinical acumen...
Clinical applications of B-type natriuretic peptidesA Mark Richards
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
Trends Endocrinol Metab 15:170-4. 2004..Recombinant B-type NP is an effective parenteral treatment in decompensated heart failure. These applications of B-type NPs require confirmation before they become established in routine management of heart failure...
B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarctionA Mark Richards
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
Circulation 107:2786-92. 2003..After acute cardiac injury, left ventricular ejection fraction (LVEF) is also of prognostic significance and plays a major role in determining the therapeutic response...
Tailored therapy for heart failure: neurohormonesA Mark Richards
Department of Medicine, University of Otago, P O Box 4345, Christchurch, New Zealand
Can J Physiol Pharmacol 89:603-7. 2011....
What we may expect from biomarkers in heart failureA Mark Richards
National Heart Foundation of New Zealand, New Zealand
Heart Fail Clin 5:463-70. 2009..Despite many promising candidates requiring fuller investigation, currently, only the natriuretic peptides satisfy these requirements...
Mineralocorticoid receptor antagonists for heart failureArthur Mark Richards
Cardioendocrine Research Group, University of Otago, Department of Medicine, PO Box 4345, Christchurch, New Zealand
Expert Opin Pharmacother 12:2801-15. 2011..MR antagonism is an important part of the pharmaceutical armamentarium in managing heart failure but must be prescribed with careful case selection, taking note of the evidence of where risks are acceptable and benefits are likely...
Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart diseaseMark Richards
Christchurch Cardioendocrine Research Group, Christchurch Hospital, Christchurch, New Zealand
J Am Coll Cardiol 47:52-60. 2006....
The natriuretic peptides in heart failureA Mark Richards
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, 4345 Christchurch, New Zealand
Basic Res Cardiol 99:94-100. 2004....
Health gains by using natriuretic peptides in diagnosis, prognosis and treatmentMark Richards
Christchurch Cardioendocrine Research Group, Christchurch, New Zealand
Scand J Clin Lab Invest Suppl 240:129-37. 2005....
Dendroaspis natriuretic peptide: endogenous or dubious?A Mark Richards
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
Lancet 359:5-6. 2002
Natriuretic peptides: update on Peptide release, bioactivity, and clinical useA Mark Richards
Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Hypertension 50:25-30. 2007
Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch, New Zealand
Circ Heart Fail 2:532-40. 2009..Because any prospective new treatment is likely to be used in conjunction with standard diuretic therapy, it is necessary to investigate the combined effects of these agents...
Long-term adrenomedullin administration in experimental heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, Christchurch, New Zealand
Hypertension 40:667-72. 2002..These findings support the concept of adrenomedullin as a protective hormone during hemodynamic compromise with therapeutic potential in heart failure...
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patientsRichard P Collins
Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
Am Heart J 152:312-20. 2006..This study aimed to corroborate the association of the AMPD1 C34T polymorphism with survival in larger myocardial infarction (MI) and HF cohorts...
Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine, Christchurch, New Zealand
Clin Sci (Lond) 114:635-42. 2008..These results indicate that dual treatment with these two agents is beneficial...
Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheepChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
J Endocrinol 189:701-10. 2006..Apelin also increases circulating levels of a number of vasoactive hormones. Taken together, these results suggest a potential role for apelin in pressure/volume homeostasis...
Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effectsMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand
Hypertension 57:1136-44. 2011..These findings support the therapeutic potential for urocortin 2 in heart failure...
Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamicsHamish C G Prosser
School of Biological Sciences, University of Canterbury, PO Box 4800, Christchurch, New Zealand
Cardiovasc Res 82:40-50. 2009....
The contrasting relationships between betaine and homocysteine in two clinical cohorts are associated with plasma lipids and drug treatmentsMichael Lever
Canterbury Health Laboratories, Clinical Biochemistry Unit, Christchurch, New Zealand
PLoS ONE 7:e32460. 2012..Urinary betaine excretion positively correlated with plasma homocysteine in outpatients attending a lipid disorders clinic (lipid clinic study). We aimed to confirm this in subjects with established vascular disease...
Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responsesMark E Davis
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
J Am Coll Cardiol 49:461-71. 2007..We sought to examine the effects of urocortin (UCN) 2 infusion on hemodynamic status, cardiovascular hormones, and renal function in healthy humans...
Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, P O Box 4345, New Zealand
Clin Sci (Lond) 102:653-60. 2002..Despite the greater falls in blood pressure (and presumably renal perfusion pressure), renal function was maintained at a level similar to that observed with captopril alone...
Hemodynamic, hormonal, and renal effects of (pro)renin receptor blockade in experimental heart failureMiriam T Rademaker
Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
Circ Heart Fail 5:645-52. 2012..The (pro)renin receptor (P)RR is implicated in blood pressure regulation and the pathophysiology of heart failure (HF). The effects of (P)RR blockade in HF have not been previously investigated...
Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failureAnna P Pilbrow
Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, 2 Riccarton Avenue, PO Box 4345, Christchurch 8140, New Zealand
Hypertension 49:322-7. 2007..0; 95% CI: 1.3 to 3.0; P=0.001). This study suggested that angiotensinogen gene variants M235T and T174M may provide prognostic information for long-term survival in heart failure patients...
Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarctionBarry R Palmer
Department of Medicine, Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch 8140, New Zealand
Eur Heart J 29:2489-96. 2008..We investigated whether aldosterone levels in patients presenting with STEMI or non-STEMI, are predictive of mortality during prolonged follow-up...
Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, Christchurch, New Zealand
Clin Sci (Lond) 106:569-76. 2004....
Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarctionLeigh J Ellmers
Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch 8140, New Zealand
Endocrinology 149:5828-34. 2008..Our findings indicate that blockade of the TGF-beta signaling pathway results in significant amelioration of deleterious cardiac remodeling after infarction...
Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during developmentNicola J A Scott
Department of Medicine, University of Otago Christchurch, P O Box 4345, Christchurch, New Zealand
Biochim Biophys Acta 1792:1175-84. 2009..The decreased viability of Npr1(-/-)embryos may result from a combination of cardiomegaly and dysregulated Cx43 protein affecting cardiac contractility...
A common variant at chromosome 9P21.3 is associated with age of onset of coronary disease but not subsequent mortalityKatrina L Ellis
Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Circ Cardiovasc Genet 3:286-93. 2010..However, the effect of rs1333049 on clinical outcomes in patients with established coronary disease has yet to be determined...
Betaine and secondary events in an acute coronary syndrome cohortMichael Lever
Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
PLoS ONE 7:e37883. 2012..Betaine insufficiency is associated with unfavourable vascular risk profiles in metabolic syndrome patients. We investigated associations between betaine insufficiency and secondary events in acute coronary syndrome patients...
The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarctionBarry R Palmer
Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand
Cardiovasc Diabetol 8:31. 2009..The association of UCP2 with baseline biochemical and hormonal measurements, including levels of the inflammatory marker myeloperoxidase, was also examined...
Antecedent hypertension and heart failure after myocardial infarctionA Mark Richards
Cardiology, Christchurch Hospital, Christchurch, New Zealand
J Am Coll Cardiol 39:1182-8. 2002..We sought to assess the relationship of antecedent hypertension to neurohormones, ventricular remodeling and clinical heart failure (HF) after myocardial infarction (MI)...
Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failureMiriam T Rademaker
Department of Medicine, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
Am J Physiol Heart Circ Physiol 293:H1536-44. 2007..These data strongly support a use for Ucn1 as a therapeutic option early in the course of the disease...
Hemodynamic, hormonal, and renal actions of adrenomedullin-2 in normal conscious sheepChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, New Zealand
Endocrinology 147:1871-7. 2006..Thus, AM-2 may be another important regulator of volume and pressure homeostasis and may play a role in the pathophysiology of heart disease...
Urocortin 1 modulates the neurohumoral response to acute nitroprusside-induced hypotension in sheepChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
Clin Sci (Lond) 112:485-91. 2007..The threshold for the action of Ucn1 on the natriuretic peptides and endothelin-1 appears to be below that of other actions of Ucn1...
Plasma concentrations of myeloperoxidase predict mortality after myocardial infarctionTessa J Mocatta
Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
J Am Coll Cardiol 49:1993-2000. 2007..This study investigated relationships between plasma myeloperoxidase (MPO), protein oxidation markers, and clinical outcome retrospectively in patients after acute myocardial infarction (MI)...
NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trialJohn G Lainchbury
The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
Eur J Heart Fail 8:532-8. 2006..CONCLUSION: We describe details of a study to test the potential utility of serial measurements of NTproBNP in adjusting the drug treatment of patients with CHF. Projected completion date is 2007...
Effect of sex steroids on plasma C-type natriuretic peptide forms: stimulation by oestradiol in lambs and adult sheepTimothy C R Prickett
Department of Medicine, University of Otago, PO Box 4345, Christchurch 8140, New Zealand
J Endocrinol 199:481-7. 2008..These results are the first to show that E(2) stimulates plasma CNP forms and bALP in lambs and adult sheep and raise the possibility that CNP also participates in bone formation in the mature skeleton...
Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand
Circ Heart Fail 1:134-42. 2008..The effects of AM2 in heart failure have not been investigated previously...
Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarctionSuetonia C Palmer
Department of Medicine, University of Otago Christchurch, 2 Riccarton Avenue, Christchurch 8140, New Zealand
Eur Heart J 30:1486-94. 2009..7%, P < 0.001). Conclusion Ten year rates of mortality and HF are 5-10 times higher when lower eGFR is present together with increased NT-proBNP or depressed LVEF...
Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac functionSuetonia C Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Hypertension 54:612-8. 2009..Taken together, differences in magnitude and direction of transorgan gradients for CNP compared with NT-proCNP suggest net generalized cosecretion with differing mechanisms of clearance...
Effect of nutrition on plasma C-type natriuretic peptide forms in adult sheep: evidence for enhanced C-type natriuretic peptide degradation during caloric restrictionTimothy C R Prickett
Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, PO Box 4345, 8140 Christchurch, New Zealand
Metabolism 59:796-801. 2010..Fall in plasma CNP but not in NTproCNP in CR adult sheep suggests that CNP degradation (not synthesis) is altered, and contrasts with previous findings in growing lambs where CR reduces both CNP forms...
Amino-terminal proCNP: a putative marker of cartilage activity in postnatal growthTimothy C R Prickett
Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch 8015, New Zealand
Pediatr Res 58:334-40. 2005..In summary, NT-proCNP levels in blood show a strong association with growth velocity and markers of bone formation and may well serve as a useful marker of growth plate activity in humans and other mammals...
Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failureMiriam T Rademaker
Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch, New Zealand
Circulation 112:3624-32. 2005..Urocortin 2 (Ucn2) has potent cardiovascular actions and may participate in the pathophysiology of heart failure (HF). The integrated hemodynamic, endocrine, and renal effects of Ucn2 are unknown...
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trialJohn G Lainchbury
Department of Medicine, Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand
J Am Coll Cardiol 55:53-60. 2009....
Effect of urocortin 1 infusion in humans with stable congestive cardiac failureMark E Davis
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch 8001, New Zealand
Clin Sci (Lond) 109:381-8. 2005..ANP and ghrelin were unchanged, and no haemodynamic or renal effects were seen. In conclusion, a brief intravenous infusion of 50 microg of Ucn 1 stimulates corticotropin and cortisol in male volunteers with stable HF...
Plasma lipids and betaine are related in an acute coronary syndrome cohortMichael Lever
Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
PLoS ONE 6:e21666. 2011..We aimed to measure the relationships between plasma and urine betaine and plasma lipids, and the effects of lipid-lowering drugs on these...
Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
Eur Heart J 26:2046-54. 2005..To investigate the role of the endogenous urocortin peptides in heart failure (HF) through blockade of the corticotropin-releasing factor receptor 2 (CRF-R2)...
CYP1A1 MSPI (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patientsMartin D Jarvis
Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand
Clin Exp Pharmacol Physiol 37:193-8. 2010..853). 4. The results indicate that the homozygous CYP1A1 6235C genotype is associated with greater mortality following the onset of ACS, independent of ethnicity and clinical risk factors, but related to smoking history...
Serial Doppler echocardiography and tissue Doppler imaging in the detection of elevated directly measured left atrial pressure in ambulant subjects with chronic heart failureJay L Ritzema
Department of Medicine, University of Otago, Christchurch, New Zealand
JACC Cardiovasc Imaging 4:927-34. 2011....
Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarctionBarry R Palmer
Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
J Am Coll Cardiol 41:729-36. 2003....
2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trialMartin Than
Christchurch Hospital, Christchurch, New Zealand
J Am Coll Cardiol 59:2091-8. 2012..The purpose of this study was to determine whether a new accelerated diagnostic protocol (ADP) for possible cardiac chest pain could identify low-risk patients suitable for early discharge (with follow-up shortly after discharge)...
Plasma amino-terminal pro C-type natriuretic Peptide in the neonate: relation to gestational age and postnatal linear growthTimothy C R Prickett
Department of Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch Mail Centre, Christchurch 8140, New Zealand
J Clin Endocrinol Metab 93:225-32. 2008..Whether correlations of NTproCNP with linear growth, as found in children and lambs, apply in neonates is unknown...
Plasma urocortin 1 in human heart failureSue P Wright
Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand
Circ Heart Fail 2:465-71. 2009..We have investigated plasma urocortin 1 as a potential diagnostic marker of heart failure and documented its relationships to symptoms, measures of cardiac function, and concurrent levels of other circulating neurohormones...
Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injuryJarkko Piuhola
Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand
Clin Sci (Lond) 114:293-304. 2008..Thus EPO directly enhances cardiac contractility and BNP secretion and alleviates ischemia/reperfusion injury via ET-1-dependent and -independent mechanisms respectively...
The effects of medications on circulating levels of cardiac natriuretic peptidesRichard W Troughton
Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Ann Med 39:242-60. 2007..In the meantime, clinicians need to consider the known effects of medications when interpreting plasma levels of the cardiac natriuretic peptides...
Adrenomedullin and heart failureMiriam T Rademaker
The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
Regul Pept 112:51-60. 2003..Manipulation of the AM system holds promise as a therapeutic strategy in cardiac disease...
Skeletal contributions to plasma CNP forms: evidence from regional sampling in growing lambsTimothy C R Prickett
Department of Medicine, University of Otago, Christchurch, New Zealand
Peptides 30:2343-7. 2009....
Natriuretic peptides maintain sodium homoeostasis during chronic volume loading post-myocardial infarction in sheepChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
Clin Sci (Lond) 104:429-36. 2003..This study provides evidence that natriuretic peptides play a pivotal role in preserving volume/electrolyte balance in the early stages of post-MI cardiac dysfunction...
Plasma urocortin 1 in sheep: regional sampling and effects of experimental heart failureChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Peptides 27:1801-5. 2006..This is the first report identifying sources of circulating Ucn-1...
Regional sampling and the effects of experimental heart failure in sheep: differential responses in A, B and C-type natriuretic peptidesChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
Peptides 27:62-8. 2006..Circulating levels of CNP and NT-CNP were raised in heart failure but to a much lesser degree than ANP and BNP. There was no evidence of net extraction of CNP or NT-CNP across any tissue bed...
Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failureMark E Davis
The Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Circulation 113:977-85. 2006....
Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable deviceJay Ritzema
Department of Cardiology, Parkside West, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand 8001
Circulation 116:2952-9. 2007..We describe the first human experience with a permanently implantable, direct left atrial pressure (LAP) monitoring system in ambulatory patients with chronic heart failure...
Adrenomedullin and the renin-angiotensin-aldosterone systemChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
Regul Pept 112:41-9. 2003..Thus, these results clearly point to a role for AM in pressure and volume homeostasis acting, at least in part, by interaction with the renin-angiotensin-aldosterone system (RAAS)...
Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatmentMathew D Littlejohn
Department of Pathology and Carney Centre for Pharmacogenomics, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand
Eur J Heart Fail 10:55-9. 2008..The Ile164 variant of the beta2-adrenoceptor has been shown to alter cardiovascular phenotypes and adversely affect survival in heart failure patients...
B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemiaMaithri Siriwardena
Department of Medicine, University of Otago, Christchurch, New Zealand
Circulation 122:255-64. 2010..However, there is a clear need to identify circulating, specific biomarkers that can detect cardiac ischemia without necrosis...
Urocortin 1 exhibits potent inhibition of cardiac sympathetic nerve activity in conscious sheepChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
J Hypertens 26:53-60. 2008..Urocortin 1 (Ucn1) and the sympathetic nervous system both participate in cardiac and circulatory regulation, but little is known about their possible interactions...
Cardiac natriuretic peptides for cardiac healthMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Clin Sci (Lond) 108:23-36. 2005..The favourable biological properties of the natriuretic peptides have also led to their use as therapeutic agents...
BNP in hormone-guided treatment of heart failureA Mark Richards
Christchurch Cardioendocrine Research Group, Dept Medicine, Christchurch School of Medicine, Riccarton Avenue, PO Box 4345, Christchurch, New Zealand
Trends Endocrinol Metab 13:151-5. 2002..This encourages further exploration of hormone guidance of anti-heart failure therapy, which could be extended to patients with preserved ejection fraction, in addition to those with established systolic dysfunction...
Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failureMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, Christchurch, New Zealand
Hypertension 39:93-8. 2002..In conclusion, cotreatment with adrenomedullin and an endopeptidase inhibitor has beneficial hemodynamic and renal effects in heart failure beyond those of either agent separately...
Early dynamic change in high-sensitivity cardiac troponin T in the investigation of acute myocardial infarctionSally J Aldous
Christchurch Hospital, Christchurch, New Zealand
Clin Chem 57:1154-60. 2011..How much troponin must change has not been specified. We ascertained whether dynamic changes (δ) in high-sensitivity troponin T (hs-TnT) improved diagnostic and prognostic test performance in the emergency department...
B-type natriuretic peptides and echocardiographic measures of cardiac structure and functionRichard W Troughton
University Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
JACC Cardiovasc Imaging 2:216-25. 2009....
Coenzyme Q10; an adjunctive therapy for congestive heart failure?Sarah L Molyneux
Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
N Z Med J 122:74-9. 2009..CoQ10 depletion may also be a contributory factor for why statin intervention has not improved outcomes in CHF. There is an emerging evidence base in support of CoQ10 as an adjunctive therapy in CHF...
Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deteriorationIvor L Gerber
Department of Cardiology, Auckland City Hospital, Auckland New Zealand
Am J Cardiol 95:898-901. 2005..Measurement of NT-pro-BNP in addition to clinical assessment and echocardiography may allow more reliable follow-up and timing of valve replacement for aortic stenosis...
Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillationAmjad K Hamid
Department of Medicine, Otago University Christchurch, Christchurch, New Zealand
N Z Med J 124:48-56. 2011..There is little recent information regarding outcome and its determinants following cardioversion (CV) for atrial fibrillation (AF) or flutter. This study aims to help improve prediction of cardiac rhythm outcome following CV for AF...
BNP for clinical monitoring of heart failureRichard W Troughton
Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Heart Fail Clin 2:333-43. 2006
Images in cardiovascular medicine. Dynamic myocardial ischemia caused by circumflex artery stenosis detected by a new implantable left atrial pressure monitoring deviceJay L T Ritzema-Carter
Christchurch Hospital, Christchurch, New Zealand
Circulation 113:e705-6. 2006
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosisRalph A H Stewart
Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
Am Heart J 156:348-55. 2008..Effects of eplerenone on LV diastolic function and progression of valve stenosis were also evaluated...
Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studiesA Mark Richards
Department of Medicine, Christchurch Cardioendocrine Research Group, New Zealand
J Card Fail 11:S34-7. 2005....
Plasma brain natriuretic peptide after long-term treatment for heart failure in general practiceGraham McGeoch
Department of Public Health and General Practice, The Christchurch School of Medicine, University of Otago, New Zealand
Eur J Heart Fail 4:479-83. 2002..Plasma BNP was assessed for its ability to predict echocardiographic abnormality in 100 patients receiving long-term treatment in general practice for a provisional diagnosis of heart failure...
Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasmaSuetonia C Palmer
Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand
Eur J Heart Fail 11:832-9. 2009..We sought to determine site(s) of production and clearance of plasma NT-proBNP in the human circulation...
Characterization of NT-proBNP in human urineSuetonia C Palmer
Christchurch Cardioendocrine Research Group, University of Otago Christchurch, New Zealand
Clin Chem 55:1126-34. 2009..We characterized the molecular forms of urine NT-proBNP detected by immunoassay...
Coenzyme Q10: an independent predictor of mortality in chronic heart failureSarah L Molyneux
Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
J Am Coll Cardiol 52:1435-41. 2008..The aim of this study was to investigate the relationship between plasma coenzyme Q(10) (CoQ(10)) and survival in patients with chronic heart failure (CHF)...
The neuro-cardio-endocrine response to acute subarachnoid haemorrhageEric A Espiner
Department of Neurosurgery, Christchurch Hospital, PB 4710, Christchurch, New Zealand
Clin Endocrinol (Oxf) 56:629-35. 2002....
Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurementRichard W Troughton
Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
Am J Cardiol 101:72-5. 2008..Adjustments in treatment and serial clinical follow-up with NT-proBNP retesting should be considered at frequent intervals until biochemical stabilization or achievement of a maximally tolerated medical program...
Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheepMiriam T Rademaker
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch, New Zealand
J Am Coll Cardiol 40:1495-505. 2002..The goal of this study was to determine the bioactivity of urocortin (Ucn) in experimental heart failure (HF)...
Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretchChris J Pemberton
Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, 2 Riccarton Avenue, P O Box 4345, Christchurch, New Zealand
Cardiovasc Res 68:109-17. 2005....
Adrenomedullin in heart failureM Gary Nicholls
Department of Medicine, Christchurch Hospital, Christchurch, New Zealand
Hypertens Res 26:S135-40. 2003..An improved understanding of the role of adrenomedullin in heart failure might lead to the development of therapeutic agents acting through adrenomedullin receptors...
Urotensin II: evidence for cardiac, hepatic and renal productionChristopher J Charles
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch 8001, New Zealand
Peptides 26:2211-4. 2005..Significant arteriovenous gradients were observed across the heart (36%), liver (40%) and kidney (44%). This is the first report to identify the heart, liver and kidney as sources of UII in the circulation...
Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?Roland R J van Kimmenade
Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
J Am Coll Cardiol 48:1621-7. 2006..We sought to study the individual and integrative role of amino-terminal pro-brain natriuretic peptide (NT-proBNP) and parameters of renal function for prognosis in heart failure...
Variability of NT-proBNP levels in heart failure: implications for clinical applicationA Mark Richards
Heart 93:899-900. 2007
Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosisIvor L Gerber
Cardiology Department, Green Lane Hospital, Auckland, New Zealand
Circulation 107:1884-90. 2003..CONCLUSIONS: Plasma natriuretic peptide levels are elevated in symptomatic patients with aortic stenosis. Measurement of natriuretic peptides may complement clinical and echocardiographic evaluation of patients with aortic stenosis...
Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspneaAntoni Bayes Genis
Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma, Barcelona, Spain
Arch Intern Med 167:400-7. 2007..An inverse relationship between body mass index (BMI); (calculated as weight in kilograms divided by height in meters squared) and NT-proBNP concentrations has been described...
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failureJeffrey W H Fung
Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
Am J Cardiol 92:406-10. 2003..These results indicate that the suppressive effect of beta blockers on PRA in patients with HF taking ACE inhibitors is temporary, and that there is no significant effect on serum aldosterone levels...
Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart diseaseCara A Wasywich
Cardiology Department, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
Am J Cardiol 97:1068-72. 2006....
Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failureRoland R J van Kimmenade
Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
Am J Cardiol 98:386-90. 2006..Mortality rates in subjects with intermediate NT-pro-BNP concentrations are lower than in those with NT-pro-BNP concentrations diagnostic for HF but are higher than in subjects with NT-pro-BNP concentrations less than the gray zone...
B-type natriuretic peptide and long-term survival in patients with stable coronary artery diseaseTorbjørn Omland
Cardiology Division, Department of Medicine, Akershus University Hospital, University of Oslo, Oslo, Norway
Am J Cardiol 95:24-8. 2005..005) provided prognostic information above and beyond conventional risk markers. In patients with clinically stable, angiographically documented coronary artery disease, plasma BNP levels are independently related to long-term survival...
N-terminal-pro-B-type natriuretic peptide: universal marker of cardiovascular risk?A Mark Richards
Circulation 112:9-11. 2005
Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertensionPer Hildebrandt
Department of Internal Medicine and Cardiology, Roskilde University Hospital, Roskilde, Denmark
Am J Cardiol 101:21-4. 2008..In this context, consideration for a more in-depth cardiovascular workup, as well as initiation or intensification of medical therapies with proven benefits might be indicated...
